1Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet, 2003, 361(9353):2247 - 2249.
2Horwitz SB. How to make taxol from scratch. Nature, 1994,367(17):593-598.
3Scollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest, 1995, 95(4): 1869 - 1876.
4Axel DI, Kunert W, Goglmann C, et al.Paclitaxel inhibits arterial smooth muscle proliferation and migration in vitro and in vivo using local drug delivery, Circulation,1997,96(3):635 - 645.
5Heldman AW, Cheng L, Jenkins GM, et al.Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronarg restenosis. Circulation, 2001, 103(18): 2289-2295.
6Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrestor growth over six mooths. J Am Coll Cardiol, 2000,36(7)2325-2332.
7Farb A, Heller PF, Shroff S, et al.Pathological analysis of local delivery of paclitaxel via a polymer-coasted stent.Circulation, 2001,104(4):473 - 479.
8Hong MK, Mintz GS, Lee CW, et al.Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: aserial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation,2003,107(4):517 - 520.
9Gershlick A, De Scheerder 1, Chevalier B,et al. Inhibition of restenosis with a paelitaxel-eluting, polymer-free coronary stent: the European evaLUation of paeliTaxel Eluting Stent (ELUTES) trial. Circulation, 2004,109(4):487-493.
10Grube E, Silber S, Hauptmann KE, et al.TAXUS Ⅰ: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation, 2003,107(1):38-42.
